Philip Jennings · Deputy Minister of Innovation, Science and Economic Development Canada (ISED), Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
and 6 moreShow fewer
Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and frameworkRead more
Free trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
John Zerucelli · Member of Parliament, and Secretary of State for Labour
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Maggie Chi · Member of Parliament, Parliamentary Secretary to Minister of Health
Nora Draper · Assistant to the Parliamentary Secretary to Minister of Health, Health Canada (HC)
Sara Kasum · Parliamentary Affairs Advisor, Minister of Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Celia Lourenco · Associate Assistant Deputy Minister, Health Canada (HC)
Daniel MacDonald · Director General, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs and One Canadian Economy, Privy Council Office (PCO)
Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister of Health, Health Canada (HC)
Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Chanel Sterie · Senior Policy Advisor, Public Services and Procurement Canada (PSPC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Maggie Chi · Member of Parliament, Parliamentary Secretary to Minister of Health
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processesRead more
Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
Free trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
François Rivest · Director General, Export Support Bureau, Global Affairs Canada (GAC)
Natalie Zakhem · Trade Commissioner, Global Affairs Canada (GAC)
Elizabeth Reid · Senior Trade Commissioner, Global Affairs Canada (GAC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Sara Kasum · Parliamentary Affairs Advisor to the Minister of Health, Health Canada (HC)
Free trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
Free trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Free trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister of Health, Health Canada (HC)
Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Free trade agreements as they relate to the biopharmaceutical industry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.